If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Trading Update

27 Jun 2016 07:00

RNS Number : 2776C
Biome Technologies PLC
27 June 2016
 

27 June 2016

 

 

Biome Technologies plc

("Biome", the "Company" or the "Group")

 

Trading Update

 

 

Biome Technologies plc, a leading bioplastics and radio frequency technology business, today publishes a trading update for the six month period ending 30 June 2016. This update is being made ahead of the period end and in place of the trading update scheduled for the end of July. The interim results are expected to be announced on 31 August 2016.

 

Trading Update

Total Group revenues for the first half are expected to be £2.2m (H1 2015 £2.1m). Whilst this revenue is marginally ahead of last year's performance, it is below that of the Board's expectations. This shortfall is due to a reduced demand for already commercialised products in the Bioplastics Division and some slippage of the Stanelco RF's division's order pipeline into the second half.

 

The Group's cash position at 27 June 2016 is £1.0m (31 March 2016: £1.6m) reflecting the current trading activity and timing of anticipated cash receipts from work in progress in the Stanelco RF division.

 

Bioplastics Division

Revenues generated by the Bioplastics Division in the first half of 2016 totalled £0.6m (H1 2015 £1.0m).

It was noted in the trading update of 25 April 2016 that revenues in the Bioplastics division in the first quarter of 2016 were £0.2m (Q1 2015: £0.5m) reflecting the timings of campaign production runs of packaging and lidding materials for the US single-serve coffee market (coffee pods). Whilst revenues recovered in Q2 2016 to £0.4m with some additional campaigns, it had been expected by the Board that this recovery would be stronger.

 

Biome has been developing a suite of related materials to enable coffee pod producers to sell biodegradable end products to the US consumer market. This is an important advance for the market and has received supportive media comment. The materials Biome has been developing comprise the outer packaging and the lid, ring and "non-woven" filter of the pod. Each part has entailed significant development cost both in time and in production testing and we have worked in a collaborative way with the manufacturers of the pods and packaging in the US to achieve success. The packaging and lid materials have completed their development stages and have been in full production from the middle of last year. The ring and filter materials are in the advanced stages of development and we expect to move into commercialisation by the end of this year with these materials. Whilst the second half of this year should be favourably impacted as the ring reaches its commercialisation phase, it has now become clear that the inflexion point of significant revenue generation will be later in the half year than the Board has previously expected as Biome's customers complete their own work to industrialise this innovative product.

 

Throughout this broad programme, Biome has been continually re-assessing the likely demand for the portfolio of the Bioplastics division's materials, although this is made difficult by fluctuating underlying market growth, the rise in demand for such bio-degradable products as they become available and, contrarily, improving efficiencies in our customers' production processes. The Group has just completed such a review and the Board continues to believe that the long-term outlook for these products remains very positive. In the short term, however, it believes the likely demand will be less than originally thought. This will result in a near-term fall in anticipated revenues. A similar review will be undertaken at the end of August, prior to the Group's Interim Statement.

 

Stanelco RF Technologies Division

Revenues for this division in the first half of 2016 were £1.6m (2015: £1.3m), slightly behind the Board's expectations. Whilst a number of the prospective orders for the second half are still being finalised, the division has a healthy enquiry book forward into 2017.

 

Group Outlook

Group revenues at the mid-year point are behind the Board's expectations. Whilst margins have been robust and the operating loss for the period is anticipated to be lower than for the same period in 2015, it will be behind the Board's expectations.

 

Whilst the Board is confident that revenue growth should accelerate in the second half of the year, it is now likely that the Group's full year performance will be significantly behind current market expectations, with the Board now expecting Group revenues for the year to 31 December 2016 to be only marginally ahead of those achieved in the prior year.

 

 

- Ends -

 

 

For further information please contact:

 

Biome Technologies plc

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

 

Allenby Capital

David Hart/Richard Short (Nominated Adviser)

Chris Crawford/Kelly Gardiner (Broker)

www.allenbycapital.com

Tel: +44 (0) 20 3328 5656

 

FTI Consulting

Oliver Winters

www.fticonsulting.com

Tel: +44 (0) 20 3727 1535

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTAKADNFBKDFAB
Date   Source Headline
15th May 20067:01 amRNSAppointment of Adviser
3rd May 20061:05 pmRNSNotifiable Interest
2nd May 20064:58 pmRNSResult of AGM
2nd May 20062:00 pmRNSAGM Statement
10th Apr 20063:12 pmRNSAnnual Report and Accounts
7th Apr 20062:46 pmRNSAdditional Listing
13th Mar 20067:02 amRNSDirectorate Change
28th Feb 20067:02 amRNSPreliminary Results
24th Feb 20067:02 amRNSCooperation with Wal-Mart
14th Feb 20069:07 amRNSAdditional Listing
14th Feb 20067:00 amRNSUS FDA approval for Starpol
9th Feb 200610:42 amRNSIsraCaps new licence terms
9th Feb 20067:02 amRNSRe: BioProgress plc
16th Dec 20057:01 amRNSFunding for R&D facility
16th Dec 20057:01 amRNSPre Close Update
14th Dec 20057:01 amRNSLandmark deal with Perseco
8th Dec 200510:25 amRNSShare Listing Application
30th Nov 20055:40 pmRNSDirectorate Change
28th Nov 20059:24 amRNSBoard Changes
8th Nov 20057:01 amRNSPatent sale process update
3rd Nov 20054:47 pmRNSExercise of Options
1st Nov 20057:02 amRNSChange of Adviser
12th Oct 20057:00 amRNSApproval of Starpol
3rd Oct 20057:00 amRNSPatent Disposal & Update
22nd Sep 20057:02 amRNSRe Agreement
12th Sep 20057:03 amRNSDevelopment of capsule
5th Sep 20057:03 amRNSRe: Completion
30th Aug 20053:30 pmRNSDoc re. Result of EGM
30th Aug 200511:08 amRNSEGM Statement
30th Aug 20057:03 amRNSRe Agreement
5th Aug 200511:15 amRNSRe posting of circular
1st Aug 20057:01 amRNSDirector Appointment
28th Jul 20057:01 amRNSUpdate re: trials with ASDA
26th Jul 20057:00 amRNSContract Win
19th Jul 20057:00 amRNSRe Agreement
5th Jul 20057:01 amRNSRe Joint Venture
29th Jun 20057:00 amRNSInterim Results
22nd Jun 20057:00 amRNSUpdate re trials with Asda
8th Jun 20055:29 pmRNSAdditional Listing
8th Jun 200510:00 amRNSAppointment of Group MD
8th Jun 20057:50 amRNSPlacing of Ordinary Shares
6th Jun 20057:01 amRNSAcquisition
3rd Jun 20053:02 pmRNSIssue of Equity
23rd May 20057:01 amRNSRe Contract
17th May 200512:12 pmRNSAdditional Listing
10th May 20057:00 amRNSUpdate re. trials with Asda
29th Apr 20053:46 pmRNSHolding(s) in Company
25th Apr 20053:27 pmRNSDirector Shareholding
22nd Apr 20052:24 pmRNSResult of AGM
22nd Apr 200511:31 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.